Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2001 1
2003 1
2005 1
2006 3
2007 3
2008 1
2009 2
2010 2
2011 5
2012 5
2013 9
2014 3
2015 4
2016 8
2017 5
2018 10
2019 9
2020 11
2021 5
2022 8
2023 14
2024 8
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study.
Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, Ko SH, Lee JH, Lee I, Lee BK, Won KC. Moon JS, et al. Among authors: won kc. Diabetes Metab J. 2023 Nov;47(6):818-825. doi: 10.4093/dmj.2023.0171. Epub 2023 Nov 24. Diabetes Metab J. 2023. PMID: 38043782 Free PMC article. Clinical Trial.
Oxidative stress: link between hypertension and diabetes.
Moon JS, Won KC. Moon JS, et al. Among authors: won kc. Korean J Intern Med. 2017 May;32(3):439-441. doi: 10.3904/kjim.2017.153. Epub 2017 Apr 28. Korean J Intern Med. 2017. PMID: 28490720 Free PMC article. No abstract available.
Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE).
Kim NH, Lee J, Chon S, Yu JM, Jeong IK, Lim S, Kim WJ, Song K, Cho HC, Yu HM, Kim KA, Kim SS, Lee SH, Kim CH, Kwak SH, Lee YH, Chung CH, Lee S, Jin HY, Lee JH, Koh G, Kim SY, Kim J, Lee JH, Kim TN, Jeon HJ, Lee JH, Jeon JH, Yoo HJ, Kim HK, Park HK, Nam-Goong IS, Hong S, Ahn CW, Yu JH, Park JH, Park KG, Park CH, Joung KH, Ryu OH, Park KY, Hong EG, Cha BS, Won KC, Chung YS, Kim SG. Kim NH, et al. Among authors: won kc. Endocrinol Metab (Seoul). 2024 Oct;39(5):722-731. doi: 10.3803/EnM.2024.1995. Epub 2024 Aug 22. Endocrinol Metab (Seoul). 2024. PMID: 39174014 Free PMC article.
A Short but Long Journey with You.
Won KC. Won KC. Diabetes Metab J. 2018 Feb;42(1):1-2. doi: 10.4093/dmj.2018.42.1.1. Diabetes Metab J. 2018. PMID: 29504301 Free PMC article. No abstract available.
Diabetes Fact Sheet in Korea 2021.
Bae JH, Han KD, Ko SH, Yang YS, Choi JH, Choi KM, Kwon HS, Won KC. Bae JH, et al. Among authors: won kc. Diabetes Metab J. 2022 May;46(3):417-426. doi: 10.4093/dmj.2022.0106. Epub 2022 May 25. Diabetes Metab J. 2022. PMID: 35656565 Free PMC article.
110 results